|
Frost & Sullivan 2012 New Product Innovation Award Recognizes Cytomedix Angel(R) cPRP Technology
GAITHERSBURG, MD, Jan 14, 2013 (MARKETWIRE via COMTEX) --
Cytomedix, Inc. (OTCQX: CMXI) (the "Company"), a regenerative
therapies company commercializing and developing innovative platelet
and adult stem cell technologies, announced today that it has
received the 2012 North American Frost & Sullivan New Product
Innovation Award for its Angel(R) concentrated platelet-rich plasma
(cPRP) system. This is an award that is presented each year by Frost
& Sullivan to a company that has developed an innovative element in a
product by leveraging leading-edge technologies. The award recognizes
the value-added features and benefits of the product and the
increased return on investment it offers to customers.
Martin P. Rosendale, chief executive officer of Cytomedix, commented,
"We are delighted to receive this award from Frost & Sullivan which
recognizes the advanced technological features and commercial
potential of our Angel system. Angel is positioned as a 'best in
class' PRP device that represents a significant engineering advance
in the separation of whole blood and bone marrow for clinical use and
offers clear competitive advantages over other currently available
systems."
"A unique feature of Angel is its flexible therapeutic output, which
allows physicians to generate customized platelet concentrates at the
point-of-care," said Aarti Shetty, research analyst at Frost &
Sullivan. "Our analysis suggests that this is a product that could
ultimately have broad use in a large number of orthopedic
procedures."
The Angel cPRP System is intended to be used in the clinic or
intraoperatively at the point-of-care for the safe and rapid
preparation of platelet rich plasma (PRP). It was initially cleared
by the FDA for whole blood processing and recently received 510K
clearance to process bone marrow aspirate to produce platelet
concentrates. The system is designed to produce consistently high
platelet yields using a fully automated process and represents a
significant engineering advance in autologous whole blood and bone
marrow separation. Angel's advantages compared with other
commercially available systems include: 1) high platelet yields, 2)
significant reduction in pro-inflammatory cells, 3) rapid processing
time, 4) adjustable hematocrit from 0%-25%, and 5) flexible final
cPRP volumes. Proprietary software automatically adjusts the
separation parameters to deliver a consistent, high quality product.
Frost & Sullivan Best Practices Awards are presented to companies in
a variety of regional and global markets that have demonstrated
outstanding achievement and superior performance in areas such as
leadership, technological innovation, customer service, and strategic
product development. Industry analysts compare market participants
and measure performance through in-depth interviews, analysis, and
extensive secondary research in order to identify best practices in
the industry.
About Cytomedix, Inc.
Cytomedix, Inc. is an autologous regenerative
therapies company commercializing innovative platelet technologies
for orthopedics and wound care with a pipeline of adult stem cell
therapies for tissue repair. The Company markets the AutoloGel(TM)
System, a device for the production of autologous platelet rich
plasma ("PRP") gel for use on a variety of exuding wounds and the
Angel(R) cPRP System, a blood processing device and disposable
products used for the separation of blood and bone marrow into red
cells, platelet poor plasma ("PPP") and PRP in surgical settings. On
February 8, 2012 Cytomedix closed the acquisition of Aldagen, a
biopharmaceutical company developing regenerative cell therapies
based on its proprietary ALDH bright cell technology, currently in a
Phase 2 trial for the treatment of ischemic stroke. For additional
information please visit cytomedix.com
About Frost & Sullivan
Frost & Sullivan enables clients to
accelerate growth and achieve best-in-class positions in growth,
innovation and leadership. The company's Growth Partnership Service
provides the CEO and the CEO's Growth Team with disciplined research
and best-practice models to drive the generation, evaluation, and
implementation of powerful growth strategies. Frost & Sullivan
leverages 50 years of experience in partnering with Global 1000
companies, emerging businesses and the investment community from over
40 offices worldwide.
Safe Harbor Statement
Statements contained in this press release not
relating to historical facts are forward-looking statements that are
intended to fall within the safe harbor rule for such statements
under the Private Securities Litigation Reform Act of 1995. The
information contained in the forward-looking statements is inherently
uncertain, and Cytomedix' actual results may differ materially due to
a number of factors, many of which are beyond Cytomedix' ability to
predict or control, including among many others, risks and
uncertainties related to the Company's ability to successfully
integrate the Aldagen acquisition, to successfully manage
contemplated clinical trials, to manage and address the capital
needs, human resource, management, compliance and other challenges of
a larger, more complex and integrated business enterprise, viability
and effectiveness of the Company's sales approach and overall
marketing strategies, commercial success or acceptance by the medical
community, competitive responses, the Company's ability to raise
additional capital and to continue as a going concern, and
Cytomedix's ability to execute on its strategy to market the
AutoloGel(TM) System as contemplated. To the extent that any
statements made here are not historical, these statements are
essentially forward-looking. The Company uses words and phrases such
as "believes," "forecasted," "projects," "is expected," "remain
confident," "will" and/or similar expressions to identify
forward-looking statements in this press release. Undue reliance
should not be placed on forward-looking information. These
forward-looking statements are subject to known and unknown risks and
uncertainties that could cause actual events to differ from the
forward-looking statements. More information about some of these
risks and uncertainties may be found in the reports filed with the
Securities and Exchange Commission by Cytomedix, Inc. Cytomedix
operates in a highly competitive and rapidly changing business and
regulatory environment, thus new or unforeseen risks may arise.
Accordingly, investors should not place any reliance on
forward-looking statements as a prediction of actual results. Except
as is expressly required by the federal securities laws, Cytomedix
undertakes no obligation to update or revise any forward-looking
statements, whether as a result of new information, changed
circumstances or future events or for any other reason. Additional
risks that could affect our future operating results are more fully
described in our U.S. Securities and Exchange Commission filings,
including our Annual Report for the year ended December 31, 2011 and
other subsequent filings. These filings are available at www.sec.gov.
Contacts:
Cytomedix, Inc.
Martin Rosendale
Chief Executive Officer
Andrew Maslan
Chief Financial Officer
David Jorden
Executive Chairman
(240) 499-2680
Media Inquiries
Michelle Linn
Linnden Communications
linnmich@comcast.net
(508) 362-3087
SOURCE: Cytomedix, Inc.
mailto:linnmich@comcast.net
[ Back To TMCnet.com's Homepage ]
|
Call Center/CRM
Info Tech 
IP Communications 
Mobile 
Green 
Satellite 
Robotics 
Internet Telephony Magazine
Click here to read latest issue
CUSTOMER 
Cloud Computing Magazine
Click here to read latest issue
M2M Evolution Magazine
